Quantcast

Latest biopharmaceutical Stories

2014-09-18 12:30:02

Liz Moench, President & CEO of MediciGroup® Inc., will Chair the Allan Lloyds Patient Recruitment and Retention Summit Asia-Emerging Markets, 2014 PHILADELPHIA and LONDON, Sept. 18, 2014 /PRNewswire/ -- It's a new era for biopharmaceutical companies. Competition for innovation, increasing clinical development costs, new technologies and a necessity to keep up with the fast-changing environment are important factors driving industry change. These factors also influence clinical trials, and...

2014-09-12 23:00:37

The increasing demand for biopharmaceutical products like vaccines and antibodies coupled with strong pipelines for biopharmaceuticals and increasing healthcare expenditure will drive the demand for cell culture products. http://www.marketsandmarkets.com/Market-Reports/cell-culture-market-media-sera-reagents-559.html (PRWEB) September 13, 2014 The “Cell Culture Market by Equipment (Bioreactor, Incubator, Centrifuge), by Reagent (Media, Sera, Growth Factors, Serum Free Media), by...

2014-09-08 12:20:37

Companies Combine Expertise and Resources to Advance Medical Countermeasures Development and Manufacturing ANNAPOLIS, Md. and ALACHUA, Fla., Sept. 8, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) and Nanotherapeutics, Inc., a privately-held biopharmaceutical company, announced today that they have formed a Strategic Alliance to advance the development of certain medical countermeasures for the U.S. biodefense market. Under the Alliance Agreement, each company will contribute its...

2014-09-08 08:28:59

REHOVOT, Israel, September 8, 2014 /PRNewswire/ -- CollPlant (TASE: CLPT), a developer and manufacturer of human collagen-based medical products has announced that Dr. Nadav Orr has been appointed Vice President of Research & Development, effective September 7, 2014. Dr. Nadav Orr brings over 15 years of experience in research and development, including 9 years in the development of Biosurgery products. Before joining Collplant, Nadav served as an Associate...

2014-09-03 08:33:57

SEATTLE and VANCOUVER, British Columbia, Sept. 3, 2014 /PRNewswire/ -- CMC Biologics, Inc., a global leader in process development and contract manufacturing, and Zymeworks Inc., a Canadian biotherapeutics company and a world leader in the development of antibody therapeutics, have entered into a Master Services Agreement for process development, formulation development and cGMP clinical manufacturing of a recombinant human IgG1 bi-specific (heterodimeric) antibody....

2014-09-03 08:32:21

SAN DIEGO, Sept. 3, 2014 /PRNewswire/ -- Ajinomoto Althea, Inc. ("Althea"), a leading provider of biopharmaceutical contract development and manufacturing services announced today that it has officially received its European GMP certificate issued by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA conducted an on-site inspection on June 19, 2014 that yielded no critical or major observations. This certification provides clearance to Althea to test commercial...

2014-09-02 20:24:39

CBR International's Scientific Experts Supporting Mapp Biopharmaceutical Pertaining to ZMAPP(TM) BOULDER, Colo., Sept. 2, 2014 /PRNewswire/ -- Dr. Jeanne M. Novak, President and CEO of Boulder, Colorado-based CBR International Corp.(®), a full-service biopharmaceutical product, clinical, medical device and regulatory development and compliance group, has been invited by Dr. Larry Zeitlin, President of Mapp Biopharmaceutical to attend the World Health Organization's Investigational...

2014-09-02 12:29:45

HERZLIYA, Israel, Sept. 2, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced its financial and operational results for the three and six month periods ended June 30, 2014. Josh Levine, CEO of XTL, stated: "There continues to be significant...

2014-09-02 08:29:36

MONROVIA, Calif., Sept. 2, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Debra Zack, M.D., Ph.D., vice president, clinical development and the appointment of Lloyd Rowland, senior vice president, chief compliance officer and general counsel. "Debra's expertise in biologics...

2014-09-02 04:20:51

Goodwin Biotechnology pioneered best-in-class practices for the development of complex Biopharmaceuticals and Antibody Drug Conjugates (ADCs) LONDON, Sept. 2, 2014 /PRNewswire/ -- Based on its recent analysis of the mammalian contract manufacturing services market, Frost & Sullivan recognises Goodwin Biotechnology with the 2014 Global Frost & Sullivan Award for Customer Value Leadership. Goodwin Biotechnology's reputation as one of the most trusted providers of mammalian contract...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'